CytoReason
CytoReason develops AI-powered computational disease models for pharmaceutical R&D, serving top global pharma companies including Pfizer, Sanofi, and Takeda with platform modules for target identification, patient stratification, and drug portfolio analysis.
- Company typePrivate
- Founded2016
- HeadquartersTel Aviv, Israel
- Headcount101–250
- GTM typeB2B
- OfferingSoftware
What CytoReason does
CytoReason develops AI-powered computational disease models that integrate molecular, clinical, and patient-level data to map treatments, patient groups, and disease mechanisms for pharmaceutical R&D. Founded in 2016 in Tel Aviv, Israel, the company's core platform trains an evidence graph on hundreds of thousands of data points spanning transcriptomic, proteomic, single-cell, and clinical datasets, enabling comparison of drugs across multiple diseases or multiple drugs within a single disease. The product portfolio includes the central Disease Model Platform plus specialized modules for Target Profiling, Disease Subtypes, Indication Assignment, Patient Stratification, Competitive Analysis, and Standard of Care MoA, as well as disease-specific models such as IBD and Influenza. In January 2026, CytoReason launched LINA, an AI agent for pharmaceutical R&D built on the computational disease models and NVIDIA NIM microservices, designed to automate scientific workflows while grounding responses in mechanistic biology to avoid the hallucinations common in general-purpose language models.
CytoReason serves a concentrated base of top-tier pharmaceutical companies through multi-year enterprise licensing agreements that include upfront payments, milestone payments, and option fees. Disclosed customers include Pfizer (partnership since 2019 across more than 20 diseases with a deal potentially worth up to $110M over five years), Sanofi (multiple IBD-related expansions, with the latest valued at up to $16M), Takeda, Ferring Pharmaceuticals, and Poolbeg Pharma. The company reports that 5-6 of the world's top 10 pharma companies use its technology, and revenue streams span technology licensing, research collaboration services, and licensing options. Distribution is primarily direct enterprise sales with a dedicated business development team targeting pharmaceutical R&D leaders, supplemented by channel partnerships (notably Helixrus for the Korean market).
The company has raised a total of $100M in disclosed funding, including $20M from Pfizer in September 2022 and an $80M round in July 2024 led by OurCrowd with NVIDIA, Pfizer, and Thermo Fisher Scientific as strategic investors. The company holds ISO 27001 certification, has established a US hub in Cambridge, Massachusetts, and has published extensively in peer-reviewed journals including Nature, Cell, and Nature Biotechnology. Operating geographies span Israel (headquarters), the United States (Cambridge hub), and Asia Pacific (via Helixrus channel partner).
CytoReason firmographics
Firmographics- Name
- CytoReason
- Legal name
- CytoReason Ltd
- Website
- https://cytoreason.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- CytoReason develops AI-powered computational disease models for pharmaceutical R&D, serving top global pharma companies including Pfizer, Sanofi, and Takeda with platform modules for target identification, patient stratification, and drug portfolio analysis.
- Ownership category
- akta.pro rank
CytoReason industry classification
Industry- Product category
- AI Drug Discovery Platform
- NAICS
- Software Publishers (5132), Scientific Research and Development Services (5417)
- SIC
- Services-Prepackaged Software (7372)
- akta.pro primary industry
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
- akta.pro secondary industry
- AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)
Keywords
Where CytoReason is headquartered
LocationHeadquarters
- HQ city
- Tel Aviv
- HQ country
- Israel
- HQ region
- Middle East
Offices2 records
Markets served
CytoReason business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations
Revenue model
- Technology Licensing and Platform Access: Multi-year licensing agreements with pharmaceutical companies for access to computational disease models and AI platform. Deals include upfront payments, milestone payments, and option fees.
- Research Collaboration Services: Funded research collaborations where CytoReason provides AI analysis and disease model development services to pharma partners. Includes supplementary project support funding.
- Technology Licensing Options: Partners can license CytoReason's platform and disease models with options to extend, generating additional licensing revenue.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Multi-year contract | Enterprise pharmaceutical licensing - custom pricing based on scope and partnership terms |
Go-to-market motion2 records
Distribution channels2 records
Marketing channels6 records
CytoReason product offering
Product offeringCore offering
CytoReason develops an AI-powered computational disease model platform that integrates molecular, clinical, and patient-level data to map treatments, patient groups, and disease mechanisms for pharmaceutical R&D. The company licenses disease-specific models (e.g., IBD, influenza) and, as of January 2026, offers LINA, an AI agent built on NVIDIA NIM microservices that allows researchers to query the disease models conversationally while avoiding hallucinations common in general-purpose language models.
Product overview
CytoReason offers a unified AI-powered computational disease model platform that serves as the core product, supplemented by specialized modules and disease-specific models. The flagship Disease Model Platform integrates petabytes of molecular data into decision-ready models, while LINA (an AI agent introduced in January 2026) acts as an intelligent interface built on NVIDIA NIM microservices. The platform includes therapeutic-area-specific modules for Target Profiling, Disease Subtypes, Indication Assignment, Patient Stratification, Competitive Analysis, and Standard of Care MoA analysis. The portfolio also includes disease-specific models such as IBD and Influenza disease models. The architecture enables scientists to identify targets, stratify patients, compare drugs across diseases, and make portfolio-level decisions.
Differentiator
Problem solved
Functional benefit
Products and services
- CytoReason Disease Model Platform
- LINA
- IBD Disease Model
- Influenza Disease Model
Quantifiable outcome
- Five of the world's top ten pharma companies use CytoReason's technology to identify new opportunities, shorten trial phases, reduce development costs, and increase likelihood of drug approval
- +2 more outcomes
Companies that use CytoReason
Customer profileNamed customers5 records
Segments3 records
Ideal customer profiles3 records
CytoReason technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability6 records
Feature6 records
CytoReason partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered secondary and core.
- TakedasecondaryValidating LINA AI agent capabilities. Jointly published data at UEG Congress demonstrating technology's potential for target discovery insights in ulcerative colitis and Crohn's disease.
- SanoficoreThird expansion of collaboration with multi-year agreement valued at up to $16 million. Fifth commercial deal of 2025. Partnership enables Sanofi scientists to utilize CytoReason's computational models for IBD and other therapeutic areas.
- Ferring PharmaceuticalssecondaryAI-driven novel target identification collaboration for IBD using CytoReason's cell-centered AI technology combined with Ferring's therapeutic knowledge.
- Crohn's & Colitis FoundationsecondaryData collaboration integrating Foundation's IBD Plexus real-world data platform with CytoReason's computational disease models to advance IBD research and enable more targeted therapies.
- Poolbeg PharmasecondaryAI analysis partnership for influenza disease progression data. Completed computational AI influenza disease model using Poolbeg's human challenge trial data to identify drug targets.
- PfizercoreExpanded multi-year partnership with $20M equity investment and options to license CytoReason's platform and disease models, potentially worth up to $110M over five years. Collaboration active since 2019 focusing on immune-mediated and immuno-oncology diseases across over 20 diseases.
- HelixrussecondaryCommercial partnership for Korean pharmaceutical market. Helixrus represents CytoReason's AI platform and professional services in South Korea, leveraging deep knowledge of Korean pharmaceutical market and extensive network.
Scale indicators7 records
Recent moves7 records
Expansion highlights7 records
CytoReason competitors and assessment
Company assessmentDirect peers
- Recursion Pharmaceuticals: AI-driven drug discovery platform combining high-throughput biology with machine learning, targeting large pharma partnerships. Most direct competitor to CytoReason in scaling AI-bio platforms for enterprise pharma; has raised and deployed substantially more capital.
- Insitro: Machine-learning-driven drug discovery and development company building predictive models of disease from large-scale data. Directly comparable to CytoReason in using AI/ML on biological data to serve pharma R&D partnerships.
- Exscientia: AI-driven precision medicine company focused on small-molecule drug discovery using its AI platform. Now operating under Recursion post-merger; historically a direct competitor using computational platforms to design and prioritize drug candidates for pharma partners.
- Schrödinger: Computational chemistry and drug design platform providing physics-based software plus AI-driven molecular design for pharma R&D. Direct competitor in serving pharma with computational drug discovery tooling, with a strong software/enterprise orientation.
- BenevolentAI: AI-driven drug discovery company using knowledge graphs and machine learning to identify new drug targets. Comparable to CytoReason in applying AI to biomedical knowledge to prioritize targets and serve pharma partners.
- Owkin: AI biotech using federated learning on multimodal patient data to accelerate drug discovery and development. Direct peer serving pharma with AI platforms, with comparable federated/multi-modal data emphasis and similar funding stage.
- Valo Health: AI-powered drug discovery platform integrating human data and computation to accelerate development. Direct peer in end-to-end AI-driven drug discovery with a focus on cardiovascular, oncology, and neurodegenerative diseases.
Emerging players
- Isomorphic Labs: Alphabet-owned commercial spinout of DeepMind's AlphaFold work, building an AI-driven drug discovery engine for pharma. Direct peer in AI-for-pharma with deep-pocketed backing; competing for the same enterprise pharma relationships.
- Iambic Therapeutics: AI-driven drug discovery company developing its own pipeline using physics-informed neural networks for molecular design. Comparable AI-bio platform; smaller and earlier-stage but with similar enterprise pharma ambitions.
Broad incumbents
- NVIDIA (BioNeMo / Clara): Strategic investor and infrastructure provider for CytoReason via BioNeMo and NIM microservices. While not a direct competitor, NVIDIA's expanding life-sciences AI platform (BioNeMo, Clara) is a broad incumbent whose roadmap could compete with or enable CytoReason's product surface.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
CytoReason social profiles
Digital presenceCytoReason compliance and trust
Trust signalCompliance1 record
CytoReason financial estimates
Financial estimateRevenue estimate
Valuation estimate
CytoReason leadership team
Management profileNumber of profiles
Profiles20 records
CytoReason funding detail
Funding detailFunding overview
Funding rounds4 records
Investors7 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
CytoReason M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about CytoReason
What does CytoReason do?
CytoReason develops an AI-powered computational disease model platform that integrates molecular, clinical, and patient-level data to map treatments, patient groups, and disease mechanisms for pharmaceutical R&D. The company licenses disease-specific models (e.g., IBD, influenza) and, as of January 2026, offers LINA, an AI agent built on NVIDIA NIM microservices that allows researchers to query the disease models conversationally while avoiding hallucinations common in general-purpose language models.
Is CytoReason a public or private company?
CytoReason is a private company. It is classified as venture growth investor backed and is currently operating.
When was CytoReason founded?
CytoReason was founded in 2016. It employs 101 to 250 people.
Where is CytoReason based?
CytoReason is headquartered in Tel Aviv, Israel, in the Middle East region.
How does CytoReason make money?
Three revenue lines are on record. Technology Licensing and Platform Access are the primary driver. The others are research Collaboration Services and technology Licensing Options.
Who are CytoReason's main competitors?
Direct peers on record are Recursion Pharmaceuticals, Insitro, Exscientia, Schrödinger, BenevolentAI, Owkin and Valo Health. Emerging players are Isomorphic Labs and Iambic Therapeutics. NVIDIA (BioNeMo / Clara) is listed as a broad incumbent.
Does CytoReason have an API?
No public API is recorded for CytoReason.
What industry is CytoReason in?
CytoReason's product category is AI Drug Discovery Platform. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 5132 and its SIC code is 7372.